Compare Dyne Therapeutics Inc. Common Stock (DYN) vs ONEOK Inc. Common Stock (OKE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs ONEOK Inc. Common Stock — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.08 (market cap $2.86B), while ONEOK Inc. Common Stock trades at $91.78 (market cap $58.87B). The key difference: ONEOK Inc. Common Stock is far larger — about 20.6× Dyne Therapeutics Inc. Common Stock's market cap, and ONEOK Inc. Common Stock pays a 4.58% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and ONEOK Inc. Common Stock for 5 Days on average.
| DYN | OKE | |
|---|---|---|
Market Cap | $2.86B | $58.87B |
Volume | 3,341,579 | 2,504,054 |
Sector | Health | Energy |
52-Week High | $26.78 | $97.51 |
52-Week Low | $14.60 | $64.31 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $2.18B | $91.73B |
Dividend Yield | — | 4.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
ONEOK (OKE) trades at $93.38, up 1.48% with a bullish technical outlook and strong fundamental performance. The stock shows solid valuation metrics with P/E of 16.13 and P/S of 1.5, supported by $33.63B revenue and $3.39B net income in 2025. Recent acquisition of Brazos Midstream's assets for $4.425B expands Permian Basin presence, while quarterly dividends remain steady at $1.07 per share.
Outlook remains positive with analyst consensus target of $98.55 (5.5% upside) and no sell ratings. Key risks include integration of recent acquisition and commodity price exposure. Earnings beat expectations in 2 of last 3 quarters, with Q3 2026 results due October 27 providing next catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About ONEOK Inc. Common Stock
ONEOK operates energy infrastructure for natural gas, natural gas liquids, and crude oil. Its assets include pipelines, processing facilities, storage, and related services.
Read more on OKE →
